2023-503281-23-00招募中2 期
A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.6 个研究点 分布在 4 个国家目标入组 12 人开始时间: 2024年6月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 6
- 主要终点
- Phase I: Occurrence of any drug-related, treatment-emergent AE up to Week 24 after drug administration
研究概览
简要总结
"Phase I: To investigate safety and tolerability of a single inhaled dose of BI 3720931 based on number of trial participants with at least one drug-related, treatment emergent AE up to Week 24 after dosing. Phase II: To demonstrate superiority of the higher BI 3720931 dose over PBO on the primary endpoint, the absolute change from baseline in FEV1pp at Week 8. If superiority for the high dose is established, superiority of the lower dose versus PBO will be tested in a hierarchical manner on the primary endpoint. "
研究设计
- 分配方式
- Randomized
- 主要目的
- Phase II: Follow up
- 盲法
- Double (Investigator, Subject, Analyst, Monitor, Carer)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female of non-childbearing potential trial participants with a CF-pulmonary phenotype and a confirmed diagnosis of CF: - Positive sweat chloride ≥60 mEq/L by pilocarpine iontophoresis OR - Genotype with 2 identifiable CF-causing mutations accompanied by one or more clinical features if sweat chloride testing is between 30 and 59 mmol/L
- •Trial participants who are not eligible for treatment with CFTRmt due to their genotype with 2 identified CFTR-mutations (including Class I CFTR gene mutations) and are also not expected to become eligible during the trial according to investigator´s opinion
- •Trial participants able to perform acceptable spirometric maneuvers according to American Thoracic Society/European Respiratory Society 2019 standards
- •FEV1pp ≥50% and ≤100% of predicted normal at Visit
- •Predicted value based on Global Lung Initiative lung function reference equations
- •Stable CF disease with no pulmonary exacerbation 4 weeks prior to the screening visit and during the screening period and stable drug- and non-drug therapy for CF in the 4 weeks prior to dosing
- •Trial participants either naïve to prior gene therapy or exposed to prior viral or non-viral gene therapies for cystic fibrosis. If prior exposure to gene therapy for CF exists, then the following applies as per investigator judgement: a. No apparent residual side effects associated with prior gene therapy as per investigator assessment, and b. Drug-free interval of -- 6 months after last dose of prior non-viral gene therapy -- 24 months after last dose of prior viral gene therapy
- •Further inclusion criteria apply.
排除标准
- •Trial participants with ongoing or planned CFTRmt, or participants not eligible for CFTRmt based on contraindications (e.g. liver failure) or who needed to withdraw CFTRmt due to intolerability are not appropriate candidates for this Phase I/II trial
- •Trial participants requiring chronic use of systemic corticosteroids or immunosuppressants to treat another condition
- •Further exclusion criteria apply.
结局指标
主要结局
Phase I: Occurrence of any drug-related, treatment-emergent AE up to Week 24 after drug administration
Phase I: Occurrence of any drug-related, treatment-emergent AE up to Week 24 after drug administration
Phase II: Absolute change from baseline in FEV1pp at Week 8 after drug administration
Phase II: Absolute change from baseline in FEV1pp at Week 8 after drug administration
次要结局
- Phase I: Occurrence of treatment response defined as change from baseline ≥5% in FEV1pp, comparing the mean of 3 pre-treatment FEV1pp measured in the screening period with the mean of 3 post treatment FEV1pp values at Weeks 4, 6, and 8
- Phase I: Absolute change from baseline in FEV1pp at Week 24 after drug administration
- Phase I: Occurrence of any DLTs up to Week 24 after drug administration
- Phase II: Absolute change from baseline in FEV1pp at Week 24 after drug administration
- Phase II: Occurrence of any SAEs up to Week 24 after drug administration
- Phase II: Occurrence of any drug-related, treatment-emergent AEs up to Week 24 after drug administration
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (6)
Loading locations...
相似试验
终止
1 期
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult SubjectsChronic Obstructive Pulmonary DiseaseNCT07267130Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.33
招募中
1 期
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
招募中
1 期
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsNCT07263594DualityBio Inc.127
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18